Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR Therapeutics, Neon Therapeutics Enter Research Collaboration

NEW YORK (GenomeWeb) – CRISPR Therapeutics and Neon Therapeutics said today that they have entered a research collaboration to explore using a combination of each company's proprietary technologies to develop novel T cell therapies.

Headquartered in Basel, Switzerland, CRISPR Therapeutics is a gene-editing company focused on developing gene-based medicines for serious diseases using a proprietary CRISPR/Cas9 gene-editing platform.

Neon Therapeutics is an immune-oncology firm developing novel cancer drugs that leverage neoantigen biology, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. The company's current lead program is a personalized neoantigen vaccine now in multiple clinical trials.

"We look forward to applying our proprietary CRISPR/Cas9 technologies in a variety of ways to generate potent T cell therapies directed against neoantigens," CRISPR Therapeutics President Samarth Kulkarni said in a statement.

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.